Effervescent Patents (Class 424/466)
-
Publication number: 20030219479Abstract: Drug delivery devices for administering an active agent or a combination of active agents to a subject are provided.Type: ApplicationFiled: April 8, 2003Publication date: November 27, 2003Applicant: Lavipharm Laboratories Inc.Inventors: Li-Lan H. Chen, Alfred Liang
-
Patent number: 6649186Abstract: Disclosed here are effervescent granules having a controllable rate of effervescence. In some embodiments, the such granules comprise an acidic agent, an alkaline agent, a pharmacologically active agent, hot-melt extrudable binder capable of forming a eutectic mixture with the acidic agent and, optionally, a plasticizer. The effervescent granules are made by a hot-melt extrusion process. The present invention also provides a thermal heat process for preparing a pharmacologically active agent containing effervescent granule. In certain aspects, the granules contain pharmacologically active agents such as narcotics, antidiarrheal agents, antiviral agents, anxiolytic agents, a cholesterol lowering agent, an alpha adrenergic blocking agent, a phenanthrene derivative. By way of example, some of the narcotics that may be included in the granules and in the process of preparing the granules include, by way of example: phenanthrene derivatives (e.g., morphine sulfate), and morphine derivatives (e.g.Type: GrantFiled: April 20, 2000Date of Patent: November 18, 2003Assignee: EthypharmInventors: Joseph R. Robinson, James William McGinity, Pascal Delmas
-
Patent number: 6645523Abstract: Paroxetine salt compositions having improved stability are formed by controlling the pH to 6.5 or less. The compositions can be made with the aide of water without significant coloration problems. The paroxetine salts include paroxetine hydrochloride salts but preferably use paroxetine sulfonate salts such as paroxetine methane sulfonate.Type: GrantFiled: August 28, 2001Date of Patent: November 11, 2003Assignee: Synthon BCT Technologies, LLCInventors: Jacobus M. Lemmens, Theodorus H. A. Peters, Frantisek Picha, Johannes J. Platteeuw, Frans van Dalen
-
Patent number: 6641838Abstract: The pharmaceutical compositions of the present invention comprise orally administerable dosage forms that use effervescence as a penetration enhancer for drugs known, or suspected, of having poor bioavailability. Effervescence can occur in the stomach, once the tablet or other dosage form is ingested. In addition to effervescence in the stomach, or as alternative technique, by the use of appropriate coatings and other techniques, the effervescence can occur in other parts of the gastrointestinal tract, including, but not limited to, the esophagus, duodenum, and colon. The site of effervescence and drug release is chosen to correspond with the segment of the gastrointestinal tract displaying maximal absorption of the formulated drug, or to gain some other therapeutic advantage.Type: GrantFiled: October 29, 2001Date of Patent: November 4, 2003Assignee: Cima Labs Inc.Inventors: S. Indiran Pather, Joseph R. Robinson, Jonathan D. Eichman, Rajendra K. Khankari, John Hontz, Sangeeta V. Gupte
-
Patent number: 6641834Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.Type: GrantFiled: September 6, 2002Date of Patent: November 4, 2003Assignee: Allergan Sales, Inc.Inventors: Orest Olejnik, Edward D. S. Kerslake
-
Publication number: 20030198669Abstract: The present invention is an improvement in the treatment of migraine headaches. By administering dihydroergotamine alone (or a combination of DHE and caffeine) major limitations of past treatments are circumvented thereby allowing for higher efficacy and fewer side effects of treatment at lower doses.Type: ApplicationFiled: November 25, 2002Publication date: October 23, 2003Applicant: R.T. Alamo Ventures I, LLCInventors: Neal R. Cutler, Anthony DiSanto
-
Publication number: 20030194435Abstract: The present invention relates to effervescent compositions containing active ingredients, in particular dry plant extracts, wherein the acid donor of the effervescent couple is constituted by a dried fruit juice with a natural acid pH, such as freeze-dried citrus fruit juice.Type: ApplicationFiled: March 31, 2003Publication date: October 16, 2003Applicant: ABOCA S.P.A.Inventor: Valentino Mercati
-
Publication number: 20030194434Abstract: A tablet body produced by compressing a mixture comprising granules of a main active ingredient, carbonate granules, and organic acid granules. Lubricant powders are attached on the surface of the tablet body, the lubricant powders being applied onto a punch and a die and transferred to the surface of the tablet body when a compressing step is executed using the punch and the die.Type: ApplicationFiled: October 2, 2002Publication date: October 16, 2003Inventors: Yasushi Watanabe, Motohiro Ohta, Kiyoshi Morimoto
-
Patent number: 6627210Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.Type: GrantFiled: July 10, 2001Date of Patent: September 30, 2003Assignee: Allergan, Inc.Inventors: Orest Olejnik, Edward D. S. Kerslake
-
Patent number: 6627221Abstract: The invention relates to a solid pharmaceutical form of administration containing a diphosphonic acid or a physiologically compatible salt thereof as the active substance, wherein the active substance is present in granulate form, optionally together with pharmaceutical adjuvants in the inner phase, and the outer phase contains a lubricant in the form of less than 5% by weight of stearic acid relative to the total weight of the form of administration.Type: GrantFiled: July 20, 2001Date of Patent: September 30, 2003Assignee: Hoffmann-La Roche Inc.Inventors: Rolf-Dieter Gabel, Walter Preis, Heinrich Woog
-
Publication number: 20030180389Abstract: A composition which acts to protect, maintain and repair connective tissue in mammals. The composition includes glucosamine, chondroitin sulfate and sulfur in an effervescent base as its major elements. The effervescent base includes one or more acids and one or more bases and may also include a starch, a flavoring agent and a coloring agent. The composition can be formed into a tablet or can be granular. The tablet or granular mixture is dissolved in a neutral pH liquid such as water for consumption purposes.Type: ApplicationFiled: March 20, 2003Publication date: September 25, 2003Inventor: Cleve Alan Phillips
-
Publication number: 20030175340Abstract: The invention provides effervescent composition comprising a bisphosphonate, an acidic compound, an alkaline effervescing component, and optionally an anti-ulcer agent and methods of treating osteoporosis in a mammal using the effervescent compositions.Type: ApplicationFiled: October 17, 2002Publication date: September 18, 2003Inventors: David McCallister, Christer Rosen
-
Publication number: 20030170301Abstract: A tablet that includes stevia, water soluble binder, water soluble lubricant, active agent, and effervescent agent.Type: ApplicationFiled: March 11, 2002Publication date: September 11, 2003Inventor: Fred Wehling
-
Patent number: 6602523Abstract: A composite material suitable for external and/or internal association with a living body comprising: a first component having a surface area greater than approximately 10 M2/gm; and a first beneficial agent associated with at least a portion of the high surface area of the first component, wherein the first component is fabricated from a material having a hardness greater than the hardness of the first beneficial agent.Type: GrantFiled: August 17, 2000Date of Patent: August 5, 2003Assignee: Technology Holding, LLC.Inventor: Ashok V. Joshi
-
Patent number: 6602520Abstract: Rapidly disintegrating preparations containing at least one active pharmaceutical ingredient and at least one excipient can be obtained by a simple process in which at least the predominant part of the complete composition of the ingredients for the preparation to be produced is granulated, the resulting granules and, where appropriate, the remainder of the ingredients are shaped in the presence of liquid virtually without pressure, and the resulting shaped articles are dried.Type: GrantFiled: January 3, 2002Date of Patent: August 5, 2003Assignee: Bayer AGInventors: Marco Schroeder, Klaus-Jürgen Steffens
-
Publication number: 20030138486Abstract: The present invention relates to methods and dosage forms for improving the bioavailability of therapeutic agents that are metabolized in the upper gastrointestinal (GI) tract. The present invention improves the bioavailability of by administering such therapeutic agents in a floating dosage form. The floating dosage forms are kept in the stomach for extended periods of time and the therapeutic agents are not immediately released after ingestion. Controlled release of such therapeutic agents from the dosage forms prevents enzyme saturation thereby improving the bioavailability of such therapeutic agents.Type: ApplicationFiled: October 29, 2002Publication date: July 24, 2003Applicant: King Pharmaceuticals ResearchInventor: Laure Patricia Njiki Ouadji
-
Publication number: 20030133976Abstract: The pharmaceutical compositions of the present invention comprise orally administerable dosage forms that use effervescence as a penetration enhancer for drugs known, or suspected, of having poor bioavailability. Effervescence can occur in the stomach, once the tablet or other dosage form is ingested. In addition to effervescence in the stomach, or as alternative technique, by the use of appropriate coatings and other techniques, the effervescence can occur in other parts of the gastrointestinal tract, including, but not limited to, the esophagus, duodenum, and colon. The site of effervescence and drug release is chosen to correspond with the segment of the gastrointestinal tract displaying maximal absorption of the formulated drug, or to gain some other therapeutic advantage.Type: ApplicationFiled: March 18, 2003Publication date: July 17, 2003Inventors: S. Indiran Pather, Joseph R. Robinson, Jonathan D. Eichman, Rajendra K. Khankari, John Hontz, Sangeeta V. Gupte
-
Patent number: 6592903Abstract: Disclosed are solid dose nanoparticulate compositions comprising a poorly soluble active agent, at least one polymeric surface stabilizer, and dioctyl sodium sulfosuccinate (DOSS). The solid dose compositions exhibit superior redispersibility of the nanoparticulate composition upon administration to a mammal, such as a human or animal. The invention also describes methods of making and using such compositions.Type: GrantFiled: February 15, 2002Date of Patent: July 15, 2003Assignee: Elan Pharma International Ltd.Inventors: Niels P. Ryde, Stephen B. Ruddy
-
Patent number: 6589555Abstract: The invention relates to a dry effervescent composition containing inulin, and optionally containing at least one vitaceutical and other active agents. The effervescent products optionally contain lubricants and essential oils and can generate magnesium malate, a therapeutic effector. The invention also relates to a dry effervescent composition containing glucosamine. The invention also encompasses methods of preparing the effervescent compositions of the invention.Type: GrantFiled: December 27, 2000Date of Patent: July 8, 2003Inventor: Mahendra Pandya
-
Publication number: 20030118645Abstract: The pharmaceutical compositions of the present invention comprise rectally and vaginally administerable dosage forms that contain effervescent agents as penetration enhancers for drugs. Effervescence occurs in the rectum or vagina, once the dosage form is administered or at a predetermined time following administration. The effervescent agents can be used alone or in combination with pH adjusting substance, which further promote dissolution and absorption of the active ingredient.Type: ApplicationFiled: February 4, 2003Publication date: June 26, 2003Inventors: S. Indiran Pather, Joseph R. Robinson, Jonathan D. Eichman, Rajendra K. Khankari, John Hontz
-
Patent number: 6579535Abstract: Chewable tablets and particulate food and pharmaceutical products are disclosed which are made from agglomerates comprising an alcohol sugar such as mannitol and a high intensity sweetener such as Aspartame from which agglomerate tablets may be directly compressed, and processes for making the agglomerates and tablets. The tablets or particulate product containing the agglomerate may contain active ingredients blended with the agglomerate or as part of the agglomerate structure. Tablets and particulate products according to the invention can contain active ingredients such as pharmaceuticals (e.g., antacids, analgesics, cough medicine, drugs, etc.) breath sweeteners, vitamins and dietary supplements, to name a few. The high intensity sweetener containing agglomerates can also be used to make solid food mix type products such as sugar free ice tea mixes.Type: GrantFiled: March 19, 2001Date of Patent: June 17, 2003Assignee: Advanced Technology Pharmaceuticals CorporationInventors: William Valentine, William K. Valentine
-
Patent number: 6569453Abstract: An administration form for acid-labile active compounds are described. The administration forms have no enteric layers and are suitable for oral administration.Type: GrantFiled: October 26, 2001Date of Patent: May 27, 2003Assignee: Altana Pharma AGInventors: Rudolf Linder, Rango Dietrich
-
Patent number: 6569463Abstract: The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutrionals, cosmeceuticals and diagnostic agents.Type: GrantFiled: March 6, 2001Date of Patent: May 27, 2003Assignee: Lipocine, Inc.Inventors: Mahesh V. Patel, Feng-Jing Chen
-
Patent number: 6565881Abstract: The present invention relates to a new type of solid balneological preparations for cosmetic, hygienic and therapeutic use, which has both the properties of a solid bath additive and those of liquid products, and is characterized especially by the addition of lipid components, vesicle forming lipids, tensides and, in some cases, mineral salts. Active components, adjuvants such as stabilizers, adsorbing substances, lubricants as well as smoothing and breakdown promoting agents may also be contained therein.Type: GrantFiled: July 13, 1998Date of Patent: May 20, 2003Assignee: Marz Pharma GmbH & Co.KgaAInventors: Eberhard Nürnberg, Kerstin Jerzembek, Rolf D. Beutler, Jürgen Ebinger, Ruth Weis
-
Publication number: 20030091629Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.Type: ApplicationFiled: October 11, 2002Publication date: May 15, 2003Applicant: CIMA LABS INC.Inventors: S. Indiran Pather, Rajendra K. Khankari, Jonathan D. Eichman, Joseph R. Robinson, John Hontz
-
Patent number: 6555581Abstract: The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as levothyroxine (T4) sodium and liothyronine (T3) sodium (thyroid hormone drugs), preferably in an immediate release solid dosage form. Also provided are methods for making and using such immediate release and stabilized compositions.Type: GrantFiled: February 15, 2002Date of Patent: April 29, 2003Assignee: Jones Pharma, Inc.Inventors: G. Andrew Franz, Elaine A. Strauss, Philip A. DiMenna, Rocco L. Gemma
-
Patent number: 6544551Abstract: The present invention relates to new solid pharmaceutical compositions containing hexadecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis, a process for the manufacture of said pharmaceutical composition, a dosage scheme for oral administration of said pharmaceutical composition in the treatment of leishmaniasis, and finally a combination comprising said solid pharmaceutical composition, antiemeticum, and/or an antidiarrhoeal.Type: GrantFiled: July 24, 2000Date of Patent: April 8, 2003Assignee: Zentaris AGInventors: Juergen Engel, Werner Sarlikiotis, Thomas Klenner, Peter Hilgard, Dieter Sauerbier, Eckhard Milsmann
-
Patent number: 6544557Abstract: An effervescent sub-lingual type composition, optionally in tablet form, comprising at least one active ingredient, one ore more fruit acids, and one or more effervescing alkalis, wherein at least the acid component(s) have been coated with protective layer of polydimethylsiloxane that substantially minimizes contact between the acid(s) and atmospheric moisture until the composition is purposely mixed with water or is used sub-lingually. A method of preparation of the effervescent compositions is also dislcosed.Type: GrantFiled: August 27, 2001Date of Patent: April 8, 2003Assignee: Pan Pharmaceutical LimitedInventor: James Selim
-
Publication number: 20030059435Abstract: The present invention relates to a stable compacted, compressed or hard tableted injectable composition, including a vaccine composition comprising at least one freeze dried antigenic component and a dissolution aid. A package containing the above injectable composition and method to facilitate immunizing a subject against a disease comprising the steps of first dissolving the compacted, compressed or hard tableted vaccine composition in a package with a diluent to form a vaccine solution, and administering the resulting vaccine solution in an amount effective for immunizing is also provided.Type: ApplicationFiled: June 10, 2002Publication date: March 27, 2003Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Gilad Gallili, Norbert Frydman
-
Patent number: 6534016Abstract: The present invention is an additive preparation which contains an additive, an organic acid, a metal carbonate compound, and a surfactant agent which is capable of rendering the surface of a collection device to have properties that cause the surface to repel the adsorption of components of a body fluid sample. The preparation effervesces when in contact with a body fluid sample, thereby efficiently dispersing the additive and surfactant in a body fluid sample.Type: GrantFiled: November 21, 2000Date of Patent: March 18, 2003Inventors: Richmond Cohen, Ajit N. Dastane
-
Patent number: 6531151Abstract: Pharmaceutical composition comprising at least one active ingredient and hydroxypropylmethylcellulose, highly substituted hydroxypropylcellulose, and/or ethylcellulose as disintegrants, in quantities less than 15% by weight of the composition and in a form providing a disintegrant effect while avoiding the formation of a continuous matrix.Type: GrantFiled: October 29, 1999Date of Patent: March 11, 2003Assignee: Galenix DeveloppementInventor: Jerome Besse
-
Publication number: 20030035833Abstract: A novel method is provided for enhancing dispersion of drug-containing particles in an aqueous medium. According to this method, a solid dosage form of the drug is provided having incorporated therein a dispersion-enhancing amount of an effervescent agent wherein (a) the dosage form is adapted for swallowing without prior disintegration in water or in the mouth, and (b) the amount of the effervescent agent is not sufficient to substantially enhance disintegration of the dosage form in the aqueous medium.Type: ApplicationFiled: December 5, 2001Publication date: February 20, 2003Inventor: Xiaorong He
-
Patent number: 6521254Abstract: Pharmaceutical dosage forms for oral administration of an antihistamine and a decongestant are disclosed. The dosage forms provide an antihistamine in an amount and formulation to exhibit antihistaminic activity in a human for greater than 22 hours; and a decongestant in an amount and formulation to exhibit stimulatory activity in a human for less than 16 hours. The formulation of the invention can be taken once per day to afford symptomatic relief of rhinitis while avoiding stimulation at night.Type: GrantFiled: January 10, 2001Date of Patent: February 18, 2003Assignee: J-Med Pharmaceuticals, Inc.Inventors: Robert E. Weinstein, Allan M. Weinstein
-
Publication number: 20030031711Abstract: A method of concurrent treatment for gastroesophageal reflux disease and nocturnal acid breakthrough is described, which comprises the delivery of an GABAB receptor agonist such as 4-amino-3-(4-chlorophenyl)butanoic acid, in the evening, in a gastric retained drug delivery system.Type: ApplicationFiled: May 20, 2002Publication date: February 13, 2003Inventors: John W. Fara, Bret Berner, Verne E. Cowles
-
Publication number: 20030026837Abstract: An effervescent solid composition of matter is provided, which comprises, as an active component, a substance selected from chitosan, its derivatives and salts thereof and a second component capable of releasing CO2 in an acidic environment.Type: ApplicationFiled: April 12, 2002Publication date: February 6, 2003Inventors: Torbjorn Mathisen, Marcus Back, Asa Hellman
-
Publication number: 20030026813Abstract: The present invention relates to a stable compacted, compressed or hard tableted injectable composition, including a vaccine composition comprising at least one freeze dried antigenic component and a dissolution aid. A package containing the above injectable composition and method to facilitate immunizing a subject against a disease comprising the steps of first dissolving the compacted, compressed or hard tableted vaccine composition in a package with a diluent to form a vaccine solution, and administering the resulting vaccine solution in an amount effective for immunizing is also provided.Type: ApplicationFiled: February 28, 2001Publication date: February 6, 2003Inventors: Gilad Gallili, Norbert Frydman
-
Patent number: 6514487Abstract: A composition containing enhanced colloidal oatmeal which utilizes other avena sativa ingredients to neutralize the discomfort, irritation and inflammation of the skin, as well as maintaining normal skin, and can be used to treat many types of discomforts, including itching; due to poison ivy, oak and sumac, insect bites, sunburn, chicken pox, hives, prickly heat, chafing, and the like while maintaining the normal pH of the skin.Type: GrantFiled: August 3, 2001Date of Patent: February 4, 2003Inventor: Teresa Leigh Barr
-
Publication number: 20030022910Abstract: The present invention is an improvement in the treatment of migraine headaches. By administering dihydroergotamine across the oral mucosa, major limitations of past treatments are circumvented thereby allowing for higher efficacy and fewer side effects of treatment at lower doses.Type: ApplicationFiled: April 26, 2002Publication date: January 30, 2003Applicant: R.T. Alamo Ventures I, Inc.Inventor: Neal R. Cutler
-
Patent number: 6509036Abstract: The pharmaceutical compositions of the present invention comprise orally administerable dosage forms that use effervescence as a penetration enhancer for drugs known, or suspected, of having poor bioavailability. Effervescence can occur in the stomach, once the tablet or other dosage form is ingested. In addition to effervescence in the stomach, or as alternative technique, by the use of appropriate coatings and other techniques, the effervescence can occur in other parts of the gastrointestinal tract, including, but not limited to, the esophagus, duodenum, and colon. The site of effervescence and drug release is chosen to correspond with the segment of the gastrointestinal tract displaying maximal absorption of the formulated drug, or to gain some other therapeutic advantage.Type: GrantFiled: October 29, 2001Date of Patent: January 21, 2003Assignee: Cima Labs Inc.Inventors: S. Indiran Pather, Joseph R. Robinson, Jonathan D. Eichman, Rajendra K. Khankari, John Hontz, Sangeeta V. Gupte
-
Publication number: 20030008005Abstract: The present invention is an improvement in the treatment of migraine headaches. By administering dihydroergotamine sublingually, major limitations of past treatments are circumvented thereby allowing for higher efficacy and fewer side effects of treatment at lower doses.Type: ApplicationFiled: July 5, 2001Publication date: January 9, 2003Applicant: R.T. Alamo Ventures, Inc.Inventor: Neal R. Cutler
-
Publication number: 20030003146Abstract: The present invention relates to a pharmaceutical composition useful for rapid disintegration, which comprises a sparingly soluble medicament held on a gel-forming water-soluble polymer as a solid dispersion, wherein it contains a salt substance that comprises an alkali and a weak or strong acid and has an endothermic standard enthalpy of solution or heat of solution. Since rapid disintegration of the pharmaceutical composition of the present invention and rapid dissolution of the medicament contained in the preparation can be made in the digestive tracts pH-independently, good bioavailability can be attained.Type: ApplicationFiled: July 9, 2002Publication date: January 2, 2003Applicant: YAMANOUCHI PHARMACEUTICAL CO., LTD.Inventors: Hirokazu Takagi, Atsushi Kajiyama, Masahiro Yanagisawa
-
Publication number: 20030003147Abstract: An effervescent formulation of alendronate contains an acid source, a carbonate source, a binder, a lubricant and optionally, flavoring agents, colorants and sweeteners.Type: ApplicationFiled: July 9, 2002Publication date: January 2, 2003Applicant: Merck & Co., Inc.Inventors: Ashok V. Katdare, Colin R. Gardner, Kenneth A. Kramer
-
Patent number: 6500458Abstract: Condensate of superoxide anion radical (SAR) abolisher exhibiting strong and stable SAR abolishing activity is provided. Hydrogen adsorbent is introduced into a solution obtained by dissolving electrolyte into purified water. The solution containing hydrogen adsorbent is introduced into both cathode and anode chambers separated by a diaphragm. With a cathode immersed in the cathode chamber and with an anode immersed in the anode chamber, electricity is applied between the cathode and the anode to electrolyze the solution. Electrolytic reduced water produced in the cathode chamber is derived, and water included in the electrolytic reduced water is evaporated.Type: GrantFiled: November 17, 2000Date of Patent: December 31, 2002Inventors: Sanetaka Shirahata, Kazumichi Otsubo
-
Patent number: 6497900Abstract: The effervescent base for the preparation of effervescent tablets and effervescent granules consists of at least one acidic and one gas-evolving component, the former of which is formed by a mixture of (predominantly) monosodium tartrate and (possibly) disodium tartrate, and optionally tartaric acid. The effervescent base is prepared by mixing tartaric acid with sodium bicarbonate and sodium carbonate containing water of crystallization and slowly reacting the mixture at a temperature increasing to about 50° C., after which further sodium carbonate containing water of crystallization is admixed and is allowed to react up to a temperature of about 60° C., and drying is then carried out, preferably in vacuo, the mixture is mixed with further, now anhydrous sodium carbonate and the product is optionally pressed to give tablets. The base may additionally comprise an acid sensitive or an alkali-sensitive pharmaceutically active substance.Type: GrantFiled: May 24, 2000Date of Patent: December 24, 2002Inventors: Gerhard Gergely, Irmgard Gergely, Thomas Gergely, Stefan Gergely
-
Patent number: 6491947Abstract: An effervescent compound is disclosed which includes a liquid ingredient, an effervescent system and optionally a solvent. The solvent may be either hydrophobic or hydrophilic, and may have low solubility with effervescent ingredients. The solvent may include an alcohol, a glycol or a glycol ether, for example, but not limited to, 2-butoxyethanol. The effervescent system used in the effervescent compound may be, for example, but not limited to, an expanded perborate salt, anhydrous, or a mixture of an expanded perborate salt, anhydrous, and oxoborate or an acid and one or more of sodium bicarbonate, sodium carbonate, potassium bicarbonate and potassium carbonate. The effervescent compound may further include any one, or all, or any combination of the following ingredients: surfactants, bleaching compositions, anti-redeposition agents, binders, lubricants, colors, fragrances, corrosion inhibitors, disinfectants, pesticides, fertilizers and/or optical brighteners.Type: GrantFiled: August 17, 2001Date of Patent: December 10, 2002Assignee: ChemLink Laboratories, LLCInventors: Ryan Giffin Moore, Hilton G. Dawson, Richard A. DeSenna, Kenneth Scott Wiley
-
Patent number: 6488961Abstract: Disclosed here are effervescent granules having a controllable rate of effervescence. In some embodiments, the such granules comprise an acidic agent, an alkaline agent, a pharmacologically active agent, hot-melt extrudable binder capable of forming a eutectic mixture with the acidic agent and, optionally, a plasticizer. The effervescent granules are made by a hot-melt extrusion process. The present invention also provides a thermal heat process for preparing a pharmacologically active agent containing effervescent granule. In certain aspects, the granules contain pharmacologically active agents such as narcotics, antidiarrheal agents, antiviral agents, anxiolytic agents, a cholesterol lowering agent, an alpha adrenergic blocking agent, a phenanthrene derivative. By way of example, some of the narcotics that may be included in the granules and in the process of preparing the granules include, by way of example: phenanthrene derivatives (e.g., morphine sulfate), and morphine derivatives (e.g.Type: GrantFiled: December 21, 1999Date of Patent: December 3, 2002Assignee: Ethypharm, Inc.Inventors: Joseph R Robinson, James W. McGinity
-
Patent number: 6472439Abstract: The present invention relates to orally administerable medicinal plant dry extracts, wherein the non-volatile phase of the extract is bound in a microdisperse form and/or in the form of a semisolid or solid solution to a first carrier which is soluble in or miscible with alcohol, soluble in or miscible with water and solid at room temperature, optionally in addition to other auxiliaries and/or additives. Optionally, a second carrier is selected from carriers which are insoluble in alcohol, insoluble in water or swellable in water and solid at room temperature, or alkaline earth metal and/or alkali metal carbonates including hydrogencarbonates.Type: GrantFiled: December 14, 2000Date of Patent: October 29, 2002Assignee: Krewel Meuselbach GmbHInventor: Detlef Schierstedt
-
Publication number: 20020146452Abstract: An acid-gas absorbing tablet including in relatively sufficient proportions an adsorbent which may be activated carbon or silica gel or a mixture thereof, potassium carbonate, polyvinylpyrrolidinone, and potassium bicarbonate. A method of absorbing acid gases from a confined environment utilizing the above tablet by inserting it into the confined environment.Type: ApplicationFiled: January 23, 2001Publication date: October 10, 2002Inventors: Stanley B. Miller, Louis Patrone, Patricia A. Ziarniak
-
Patent number: 6461638Abstract: Pharmaceutical compositions for rectal administration comprising an effervescent mixture comprising sodium bicarbonate and glutamic acid or pyroglutamic acid with at least one diluent adapted for rectal administration, said mixture being effervescent.Type: GrantFiled: May 25, 1999Date of Patent: October 8, 2002Assignee: Techni-PharmaInventor: Axelle Note-Simonnard
-
Patent number: 6461650Abstract: The invention concerns a preparation for supplementing a beverage as a combined product for simultaneous or separate use or to be formed in situ comprising an efficient dose of calcium carbonate or of magnesium hydroxycarbonate in a Ca/Mg weight ratio ranging between 1 and 6, such that the resulting beverage is enriched in calcium or magnesium in soluble form. The invention also concerns a method for enriching a beverage in calcium and magnesium with said supplementing preparation.Type: GrantFiled: October 16, 2000Date of Patent: October 8, 2002Assignee: Institut National de la Recherche AgronomiqueInventor: Christian Remesy